Table I.
Baseline demographic and clinical patient characteristics with implanted O-ZES (n = 15)
| Parameter | Result |
|---|---|
| Age [years] | 67 ±7 |
| Male gender, n (%) | 11 (73) |
| UA/SCAD, n (%) | 13 (86)/2 (14) |
| Risk factors, n (%): | |
| Hypertension | 13 (86) |
| Hyperlipidemia | 15 (100) |
| Diabetes mellitus | 4 (26) |
| Current smoking | 10 (66) |
| Pharmacological therapy, n (%): | |
| Aspirin | 15 (100) |
| Clopidogrel | 11 (73) |
| Ticagrelor | 4 (27) |
| β-Adrenergic antagonist | 12 (80) |
| Calcium channel antagonist | 4 (27) |
| ARB/ACEI | 14 (93) |
| Statin | 14 (93) |
| Other lipid-lowering therapy | 3 (20) |
| Oral antidiabetics | 3 (20) |
| Insulin | 2 (13) |
| Laboratory results: | |
| Total cholesterol, median (IQR) [mg/dl] | 145 (131–179) |
| LDL cholesterol [mg/dl] | 79 (70–100) |
| HDL cholesterol [mg/dl] | 44 (39–53) |
| Triglyceride [mg/dl] | 106 (91–169) |
| GFR, mean ± SD [ml/min/1.73 m2] | 79.06 ±17.58 |
UA – unstable angina, SCAD – stable coronary artery disease, ARB – angiotensin II receptor blocker, ACE – angiotensin-converting-enzyme inhibitor, LDL – low-density lipids, HDL – high-density lipids, GFR – glomerular filtration rate.